INCIDENCDE OF RESISTANCE OF CLOPIDOGREL AFTER CORONARY INTERVENTION IN MAYO HOSPITAL LAHORE

BACKGROUND: Dual antiplatelet therapy (APD) is the cornerstone of management of coronary artery disease in coronary interventions. The resistance pattern against clopidogrel in our influenza is unknown. The aim of this study was to evaluate the frequency of resistance / hypoactivation to Clopidogrel after percutaneous coronary intervention (PCI) in the Pakistani population. METHODS: The study was conducted in the Mayo hospital, Lahore for 1 year period From June 2016 to June 2017. After informed consent, patients who underwent PCI were received 4 weeks ago. All patients received 600 mg Clopidogrel 4 to 6 hours before PCI and received 75 mg Aspirin and Clopidogrel 75 mg twice daily in addition to their routine medications. Venous blood samples were collected from all selected patients and a blocking analysis test was performed on P2Y12. The test has a "Closing Time" measured within the seconds. Patients were labeled as resistant (closing time <106 seconds), hypo-receiver (closing time between 106 and 224 seconds) and receiver (closing time> 225 seconds) based on this time. Demographic data and coronary risk factors were observed for all patients. Findings: Fifty patients (38 males and 12 females) were studied. Fifteen (30%) patients responded completely to Clopidogrel-resistant, 5 (10%) hypertensive and 30 (60%) closing time criteria. None of them had a clinically significant coronary event 4 weeks after PCI. CONCLUSION: More than 1/3 of the post-PCI patients are more likely to be resistant or hypoactive to clopidogrel. Keywords: Clopidogrel, P2Y12 platelet antiaggregation.